Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Average Rating of “Moderate Buy” by Brokerages

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the sixteen ratings firms that are presently covering the company, MarketBeat reports. Five research analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average twelve-month price objective […]

Leave a Reply

Your email address will not be published.

Previous post Chicago Bulls players voice frustration in a team meeting after season-opening loss: ‘It’s unacceptable’
Next post South Africa September 2023: Haval (+43.7%), Ford (+26.9%) shine in market off -4.1%